With September marking National Prostate Cancer Awareness Month and the kick-off of the 2015 NFL season, the Urology Care Foundation and the NFL have renewed their commitment to driving prostate health awareness, as well as teamed up to highlight a Public Service Announcement (PSA) focused on educating men about prostate cancer and encouraging them to take charge of their health through the Know Your Stats® campaign.
The Know Your Stats® campaign is a rallying force to connect, educate and inspire men across the country to know their prostate cancer risk and talk to their doctor about whether prostate cancer testing is right for them.
“It is important for men to know their risk and talk to their doctors so they can determine if prostate cancer testing is right for them,” said Richard A. Memo, MD, Chair of the Urology Care Foundation. “Having the tools and facts empowers individuals and their doctors to make informed decisions.”
Prostate cancer is the second most common cancer in America, affecting one in seven men. Odds increase to one in five if they are African American and one in three if they have a family history; however, the educational tools are making an impact. More men are talking with their doctors and getting tested, and fewer men are dying from the disease.
To view the multimedia release go to:
http://www.multivu.com/players/English/7365551-prostate-cancer-know-your-stats-psa/
ProSight Specialty® Insurance today announced the launch of Music Mends℠, a one-of-a-kind enhancement that’s unique in the traditionally-bound insurance industry. Music Mends is specially designed for touring artists, and is in response to the pain and disruption that terrorism invokes in our modern society. Specifically, the coverage is designed to provide support to touring artists who wish to help mend communities following an act of terrorism that interrupts a live performance. The cost of this enhancement is being borne by ProSight, in a demonstration of unprecedented commitment to artists and performers in the wake of a terrorist attack.
“The idea of Music Mends came to us after we attended a concert together and learned that some of the performers had been impacted by the terrorist attack in Paris at the Bataclan concert hall,” said ProSight Chief Underwriting Officer Bob Bailey, speaking of himself and Joe Beneducci, ProSight’s founder and CEO. “The raw emotion from the band that night was evident, and we knew we needed to do something to help support artists who want to go back and perform for their fans. That’s when the idea for Music Mends was born.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7870251-prosight-launches-music-mends/
PRONOVIAS, the leading bridal fashion firm, delighted more than 2,000 guests at the firm's catwalk show at the MNAC in Barcelona, for the presentation of the Atelier Pronovias 2018 Collection. The firm gathered celebrities from the world of fashion and film, Spanish and international socialites, press and buyers from around the world. The audience enjoyed the fashion show with a unique mise-en-scene, under a theme called “WISH” with a spectacular wishing well at center stage.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8091251-pronovias-fashion-show-2018/
Progresso is now using only 100 percent antibiotic and hormone free chicken breasts in all of its 36 chicken soup varieties. Currently available on store shelves nationwide, Progresso is the first large retail soup brand in the United States to have antibiotic and hormone free chicken breasts in its soups.
For decades, Progresso has been committed to continuously improving the quality of its soups. Not only is Progresso now using only white breast meat chicken with no antibiotics or hormones, but the brand is also free from artificial flavors and has removed artificial colors from 60 percent of its soups, with a goal to remove 100 percent by 2019. In addition, the soup brand has reduced sodium levels in more than 40 soup varieties, added seven soups to its certified Gluten Free product line and is increasing its vegetarian soup options.
To view the multimedia release go to:
http://www.multivu.com/players/English/7885251-progresso-antibiotic-free-chicken/
Sometimes, a reliable set of wheels is all that stands between a veteran and their dreams. This month, more than 100 veterans and their families will be getting keys to newly-refurbished vehicles as part of Progressive’s fifth annual Keys to Progress® event. This year, Progressive will donate its 500th vehicle. The vehicle giveaways will occur on November 9 at 68 locations across the country, including Progressive Service Centers, one-stop facilities where Progressive handles claims and coordinates repairs for customers.
To view the multimedia release go to:
https://www.multivu.com/players/English/8204351-progressive-keys-to-progress/
The following statement is being issued by Branstetter, Stranch & Jennings, PLLC regarding In re Prograf Antitrust Litigation.
A lawsuit is currently pending claiming that Astellas Pharma US, Inc. (“Astellas” or “Defendant”) violated state antitrust, unfair competition, consumer protection, and unjust enrichment laws of certain states by delaying the availability of a less expensive generic version of the immunosuppressant prescription drug Prograf® (known as tacrolimus). Plaintiffs allege that Defendant’s conduct caused some consumers and third party payors to pay too much for Prograf in certain states from September 3, 2008 to December 31, 2010 (also referred to as the “Class Damage Period”). This lawsuit does not claim that Prograf is unsafe or ineffective. Astellas denies any wrongdoing.
To view the multimedia release go to:
http://www.multivu.com/players/English/7933851-prograf-antitrust-class-action-settlement/
Personalised Medicine is the future of cancer treatment, but it presents major challenges for doctors and health services, the President of the European Society of Medical Oncology has said. Professor Rolf Stahel was speaking ahead of the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7430351-professor-rolf-stahel-astellas-debate/
Maggiano’s Little Italy® is a go-to, Guest favorite for special occasions ranging from birthdays and anniversaries to weddings and graduations. In 2016, the restaurant was host to more than 535,000 celebrations. Today, Maggiano’s will add another reason for Guests to celebrate weekly: Brunch. The restaurant, known for its made-from-scratch Italian-American cuisine, will introduce 12 new menu items created from a labor of love by its culinary trained chefs.
“Brunch is not just a meal. It’s a celebration. And, that’s what we specialize in – creating memorable events in our dining and banquet rooms,” said Steve Provost, president of Maggiano’s Little Italy. “It is a natural next step for Maggiano’s chefs to introduce our authentic and indulgent culinary twist on this beloved weekly celebration.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8012051-maggianos-little-italy-brunch-new-menu-maggbrunch/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
L’Oréal announced the winners of its International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” at the 23rd World Congress of Dermatology taking place in Vancouver, Canada.
For Africa and Arab States
Prof. Khalid Mohammed AlGhamdi from Saudi Arabia
Charity Society known as Faal to empower and support vitiligo patients in Saudi Arabia
Vitiligo is a long-term skin condition that causes pale, white patches on the skin due to a lack of melanin. This project aimed to increase awareness via TV broadcasts, schools visits and to provide psychological and social support to patients with vitiligo through training courses and different education programs.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7554651-loreal-announces-2015-awardees/
Educators engage with the most vulnerable populations and good intentions aren’t enough to drive decisions. Ethics goes beyond a simple right vs. wrong and there is a clear and compelling gap in educators’ professional continuum. Now, the research-based ProEthica™ program offers educators techniques and strategies for improving awareness of professional risks and vulnerabilities, and for the application of professional ethics in daily decision making.
Developed by Educational Testing Service (ETS), the ProEthica online educator ethics training program is research-based and designed for teachers and educational leaders. Through a series of interactive modules that combine instruction and checks for understanding, the ProEthica program uses real-life scenario-based simulations and activities to help educators establish an understanding of ethical principles and decision making, and learn how to apply them in their daily practice.
To view the multimedia release go to:
http://www.multivu.com/players/English/7798251-ets-proethica-teacher-training/
The sixth annual Productive Innovation Index released by IDEA Pharma today, which ranks biopharmaceutical companies by their ability to successfully bring innovations to market, sees Johnson & Johnson top the industry for the fourth year running.
The Productive Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it?
The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of 1st place across the past four years’ rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga® (prostate cancer), Imbruvica® (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi®/Simponi Aria® (rheumatoid arthritis), Stelara® (psoriasis and psoriatic arthritis), Invega Sustenna® and Invega Trinza® (schizophrenia).
To view the multimedia release go to:
http://www.multivu.com/players/uk/7770851-johnson-and-johnson-tops-idea-pharma/
